Although the prevalence of diabetes mellitus in hospitalized patients remains unknown, an estimated one-fourth of inpatients experience hyperglycemia.1 Hyperglycemia is linked to poor health outcomes, and there is evidence that intensive glucose control in the hospital reduces mortality, need for dialysis, infections, and length of stay.2 The American Diabetes Association (ADA) publishes clinical practice guidelines annually, which offer clinicians, patients, researchers, and payers current, evidence-based recommendations on all components of diabetes care, general treatment goals, and tools to evaluate the quality of care. The updated guidelines focus on changes in the recommendations for care of the hospitalized diabetes patient.
Data from a phase 3 trial comparing panitumumab (Vectibix) to cetuximab (Erbitux) for the treatment of wild-type KRAS metastatic colorectal cancer (mCRC) in patients who have not responded to chemotherapy, provide the oncology community with important information on the use of EGFR inhibitors for patients with mCRC.
In an effort to help facilitate accurate and uniform records of US vaccine usage, the Centers for Disease Control and Prevention (CDC) and immunization community stakeholders are exploring the potential of 2-dimensional (2D) barcoding to streamline immunization practices.
Dapagliflozin produces larger reductions in HbA1c in individuals who have higher baseline levels.
Many patients suffer from both hypertension and high cholesterol, putting them at greater risk of coronary heart disease (CHD). Controlling the hypertension and high cholesterol would reduce CHD risk by 50% or more, but less than a third of patients have achieved adequate control of both, according to an online study in Circulation.
The new update to the 2009 American Society of Clinical Oncology (ASCO) guideline on the pharmacologic interventions for breast cancer risk reduction now lists aromatase inhibitor exemestane (Aromasin, Pfizer) as an option for postmenopausal women for primary risk reduction that are at an increased risk of developing invasive breast cancer.